Short answer
Beam Therapeutics Inc. (BEAM) filed an 8-K current report with the SEC on February 24, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition). $500M senior secured term loan from Sixth Street; only $100M drawn at close, remaining $400M milestone-gated on FDA BLA acceptance, approval, and risto-cel revenue targets.
Beam Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $500M senior secured term loan from Sixth Street; only $100M drawn at close, remaining $400M milestone-gated on FDA BLA acceptance, approval, and risto-cel revenue targets
- Interest rate: 3-month SOFR + 6.50% (1.00% floor), interest-only quarterly payments with full principal bullet due Feb 2033
- Collateral: first-priority lien on substantially all assets including IP; meaningful encumbrance on Beam's core base-editing technology portfolio
- Liquidity covenant triggers if market cap falls below $1.75B: minimum cash floors scale from $40M → $80M → $125M as additional tranches are drawn
- Convertible note cap set at $400M outstanding: limits near-term dilutive financing flexibility while restricting M&A, asset sales, and additional debt
Item 2.02 · Results of Operations and Financial Condition
- Q4 2025 earnings reported Feb 24, 2026: full results in Exhibit 99.1 press release
- BEAM is a clinical-stage gene editing company; revenue/burn rate and cash runway are key investor metrics to track in the release
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Beam Therapeutics Inc. 8-K filings
Get the next BEAM 8-K as it lands
Follow BEAM for push alerts, or ask the research agent what this filing means.